Cydney Bullock-Tipton
Endocrinology, Diabetes & Metabolism · Merrillville, INNPI 1801325972
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.8% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations.
Across 186 payments — averaging $23.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$714
- Recordati_rare_diseases_inc.$436
- Abbott$425
- Insulet Corporation$419
- Novo Nordisk$413
- Xeris Pharmaceuticals, Inc.$286
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,08592%
- Education$3638%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 29 | $714 |
| Recordati_rare_diseases_inc. | 27 | $436 |
| Abbott | 26 | $425 |
| Insulet Corporation | 7 | $419 |
| Novo Nordisk | 13 | $413 |
| Xeris Pharmaceuticals, Inc. | 14 | $286 |
| Lilly USA, LLC | 14 | $246 |
| Madrigal Pharmaceuticals | 6 | $221 |
| Ascendis Pharma Endocrinology Inc | 4 | $161 |
| Tandem Diabetes Care, Inc. | 3 | $159 |
| Hologic Sales And Service, LLC | 2 | $158 |
| Corcept Therapeutics | 8 | $157 |
| Bayer | 8 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $78 |
| AstraZeneca | 3 | $66 |
| Radius Health, Inc. | 3 | $48 |
| Ascensia Diabetes Care US Inc. | 2 | $43 |
| BETA Bionics, Inc. | 2 | $34 |
| Averitas Pharma Inc. | 1 | $27 |
| Sequel Med Tech, LLC | 1 | $24 |
| Boehringer Ingelheim | 1 | $24 |
| Antares Pharma, Inc. | 1 | $23 |
| TG Therapeutics, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Mannkind Corporation | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| CSL Behring | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,448 in reported general payments places this provider in the 65th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 50 | $75,263 |
| FarxigaDapagliflozin Propanediol | 11 | $16,152 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $5,720 |
| Humalog Kwikpen U-100Insulin Lispro | 18 | $5,137 |
| Glipizide | 16 | $494 |
| Metformin Hcl | 37 | $366 |
| Atorvastatin Calcium | 35 | $204 |
| Glimepiride | 19 | $145 |
| Losartan Potassium | 15 | $111 |
| Easy Touch Alcohol Prep PadsAlcohol Antiseptic Pads | 12 | $58 |
| Alcohol Prep PadsAlcohol Antiseptic Pads | 12 | $29 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $413 | $75,26350 claims |
| AstraZenecaFarxiga | $66 | $16,15211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Merrillville
- Nihad MuhrezMerrillville$271K
- Pooja KinkhabwalaMerrillville$68K
- Richard LongleyMerrillville$3K
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.